Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Conte

Showing results (201-210 of 225) with videos related to

Pageof 23
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerM E Robson, N Tung, P Conte, et al.
Infection and Immunity|September 8, 2016
The Adherent/Invasive Escherichia coli Strain LF82 Invades and Persists in Human Prostate Cell Line RWPE-1, Activating a Strong Inflammatory ResponseMaria P Conte, Marta Aleandri, Massimiliano Marazzato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2018
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2018
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over timeG Pasello, G Zago, F Lunardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2026
Genomic Determinants of Response to Alpelisib Plus Fulvestrant in the SOLAR-1 TrialD Juric, H S Rugo, A Reising, et al.
Breast (Edinburgh, Scotland)|October 11, 2011
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial designW Eiermann, J Bergh, F Cardoso, et al.
Breast (Edinburgh, Scotland)|June 24, 2016
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity studyG Curigliano, P Gómez Pardo, F Meric-Bernstam, et al.
Inflammation|August 16, 2011
Modulation of inflammatory processes by leaves extract from Clusia nemorosa both in vitro and in vivo animal modelsJosé Alex C Farias, Jamylle Nunes S Ferro, Juliane P Silva, et al.
Pageof 23

Showing results (201-210 of 225) with videos related to

Sort By:
Pageof 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerM E Robson, N Tung, P Conte, et al.
Infection and Immunity|September 8, 2016
The Adherent/Invasive Escherichia coli Strain LF82 Invades and Persists in Human Prostate Cell Line RWPE-1, Activating a Strong Inflammatory ResponseMaria P Conte, Marta Aleandri, Massimiliano Marazzato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2018
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2018
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over timeG Pasello, G Zago, F Lunardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2026
Genomic Determinants of Response to Alpelisib Plus Fulvestrant in the SOLAR-1 TrialD Juric, H S Rugo, A Reising, et al.
Breast (Edinburgh, Scotland)|October 11, 2011
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial designW Eiermann, J Bergh, F Cardoso, et al.
Breast (Edinburgh, Scotland)|June 24, 2016
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity studyG Curigliano, P Gómez Pardo, F Meric-Bernstam, et al.
Inflammation|August 16, 2011
Modulation of inflammatory processes by leaves extract from Clusia nemorosa both in vitro and in vivo animal modelsJosé Alex C Farias, Jamylle Nunes S Ferro, Juliane P Silva, et al.
Pageof 23